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1 |  INTRODUCTION
The relatively recently described glycoprotein nonmet-
astatic melanoma protein B (GPNMB) is also known as 
dendritic cell-heparin integrin ligand (DC-HIL, mouse or-
tholog), osteoactivin (OA, rat ortholog), and hematopoietic 
growth factor inducible neurokinin-1 type (HGFIN). The 
gene encoding GPNMB was first identified from a subtrac-
tive cDNA screen of human melanoma cells with different 
metastatic potential.1 It acquired its name from preferen-
tially being expressed at high levels in a melanoma cell 
line with low metastatic potential. GPNMB shares high 
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Abstract
The glycoprotein nonmetastatic melanoma protein B (GPNMB, also known as os-
teoactivin) is highly expressed in many cell types and regulates the homeostasis in 
various tissues. In different physiological contexts, it functions as a melanosome-
associated protein, membrane-bound surface receptor, soluble ligand, or adhesion 
molecule. Therefore, GPNMB is involved in cell differentiation, migration, inflam-
mation, metabolism, and neuroprotection. Because of its various involvement in 
different physiological conditions, GPNMB has been implicated in many diseases, 
including cancer, neurological disorders, and more recently immune-mediated dis-
eases. This review summarizes the regulation and function of GPNMB in normal 
physiology, and discusses the involvement of GPNMB in disease conditions with a 
particular focus on its potential role and therapeutic implications in autoimmunity.
K E Y W O R D S
autoimmunity, GPNMB, lupus, osteoactivin, vasculitis
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sequence homology with a common melanocytic protein 
called premelanosome protein (PMEL17/gp100), which is 
critical for pigment biogenesis in melanocytes. It also shares 
homology, to a lesser extent, with lysosome-associated 
membrane proteins (LAMPs) which are glycosylated pro-
teins found abundant in lysosomal membranes.2 Since the 
discovery of GPNMB, studies have shown that this protein 
is highly expressed in a variety of tumors, including breast 
cancer, glioblastoma, and lung cancer, to name a few.3-5 
In addition, this protein promotes tumor growth as well as 
tumor invasion and metastasis.6-8
Although GPNMB was recently identified, significant re-
search on the function and regulation of GPNMB has been 
performed to dissect the molecular complexities of this 
protein in various diseases. Furthermore, recent evidence 
suggests a role for GPNMB in immune regulation and im-
mune-mediated diseases. This review comprehensively dis-
cusses current knowledge of GPNMB structure and function, 
as well as implications of GPNMB dysregulation in autoim-
munity and its potential as a therapeutic target in autoimmune 
diseases.
2 |  GPNMB STRUCTURE
The GPNMB gene, mapped to chromosome 7p15.1, encodes 
a type I transmembrane glycoprotein that has two isoforms 
due to alternative splicing. The length of the protein is 572 vs 
560 amino acids9; the longer variant contains a 12 amino acid 
insertion within the extracellular GAP1 domain (Figure 1). 
There are no reports suggesting that the short and long iso-
forms possess different functions.
By homology modeling prediction, GPNMB contains an 
extracellular domain, a single-pass transmembrane domain, 
and a 53 amino acid cytoplasmic tail.10 The extracellular do-
main has an N-terminal signal peptide (SP), an integrin-bind-
ing RGD motif embedded in the N-terminal domain (NTD), 
a polycystic kidney disease (PKD) domain, and GAP1 and 
GAP2 domain separated by a Kringle-like domain (KLD, 
Figure 1). There are 12 potential N-glycosylation sites in the 
extracellular domain and these N-glycans are linked to aspar-
agine residues. In immunoblots, human GPNMB is detected 
at around 90 and 115 kDa as the precursor and mature forms, 
while the un-glycosylated form is detected around 65 kDa. 
F I G U R E  1  Structure of GPNMB. 
This membrane-bound protein contains 
a signaling domain (SP), an RGD motif 
in the N-terminal domain (NTD), a 
polycystic kidney disease (PKD) domain, 
and a Kringle-like domain (KLD) in the 
extracellular portion. The cytosolic domain, 
which is separated by the transmembrane 
domain (TM), consists of a half 
immunoreceptor tyrosine-based activation 
motif (hemITAM), and a lysosomal/
endosomal targeting dileucine motif (DL) 
in the C-terminal domain (CTD). Solid stars 
indicate potential N-glycosylation sites. 
A GPNMB isoform is identified where 12 
amino acids are inserted between amino acid 
339 and 340 in GAP1, most likely due to 
alternative splicing
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The SP domain is believed to send GPNMB into a secretory 
pathway.10 The RGD motif is well characterized as an inte-
grin-binding motif, critical for GPNMB-mediated cell adhe-
sion, migration, and proliferation.11-14 The PKD domain is an 
immunoglobulin-like folding structure with possible roles in 
mediating protein interactions and cell adhesion.15 It is sug-
gested that the invasive capacity of GPNMB in breast cancer 
cells is dependent on this domain.16 The PKD domain also 
distinguishes the trafficking and amyloidogenic properties 
between GPNMB and its homolog PMEL; the differences 
of these properties are due to the extensive glycosylation of 
the PKD domain of GPNMB.17 In addition, GPNMB inter-
acts with syndecan-4 on activated T cells through the PKD, 
which leads to suppression of T cell activation and prolifer-
ation.18 The KLD is conserved across species and recently 
shown to be critical in controlling the tumorigenic potential 
of GPNMB, as the KLD deletion mutant not only affected the 
molecular functions of GPNMB, but also reduced its ability 
to promote cell migration.19
The half immunoreceptor tyrosine-based activation 
(hemITAM) motif located in the C-terminal domain (CTD) 
contains a highly conserved YxxI sequence. The tyrosine 
residue in hemITAM can be phosphorylated thereby leads to 
the activation of several downstream pathways. For instance, 
the epidermal growth factor receptor (EGFR) interacts with 
GPNMB and this induces tyrosine phosphorylation in the 
hemITAM, which correlates with poor prognosis of breast 
cancer patients.20 The hemITAM is also essential for the in-
duction of epithelial-mesenchymal transition, tumorigenic 
activities, and stem-like properties of GPNMB.21,22 In addi-
tion to the hemITAM domain, GPNMB also has a dileucine 
(DL) motif in the cytoplasmic tail. The D/ExxxLL sequence 
is believed to be associated with receptor internalization and 
lysosomal/endosomal targeting.23
Interestingly, GPNMB can undergo proteolytic process-
ing to form a 20kDa C-terminal fragment.24 This only oc-
curs with the mature form of GPNMB (115 kDa protein).10 
In breast cancer cells, ADAM10 was identified as a sheddase 
that can release the GPNMB ectodomain, which induces en-
dothelial cell migration.25 In fibroblasts, the ectodomain of 
GPNMB induces MMP-3 production via ERK activation.26
3 |  GPNMB REGULATION
3.1 | Epigenetics
GPNMB is regulated by epigenetic mechanisms. Methylation 
at the promoter region of GPNMB has been documented in 
colorectal cancer.27,28 Hypermethylation of GPNMB was 
found in 95% of the patients with colorectal cancer, while 
only 20% of healthy subjects.27 In addition, GPNMB methyl-
ation status correlates with cancer progression, as it is lower 
in early colorectal cancer stages and higher in advanced can-
cer. An inverse relationship between methylation status and 
protein expression was also noted. Interestingly GPNMB 
showed tumor-suppressive effects in human colorectal can-
cer cells.
In addition to DNA methylation, GPNMB might be con-
trolled by histone acetylation. Treating gastric cancer cells 
BGC-823 with a histone deacetylase inhibitor trichostatin A 
(TSA) significantly downregulated GPNMB expression.29 
Since GPNMB is elevated in advanced gastric carcinoma tis-
sue and TSA significantly induced cell apoptosis, the authors 
suggested that GPNMB might be involved in TSA-induced 
apoptosis in gastric cancer. In breast cancer cells, GPNMB 
has been shown to be one of the target genes of the enhancer 
of zeste homolog 2 (EZH2), a histone methyltransferase.30 
Using gene expression profiling arrays in EZH2-knockdown 
breast cancer cells coupled with analyzing ChiP-seq datasets, 
GPNMB was identified to be an EZH2-target gene. Since 
EZH2-mediated H3K27me3 is a repressor mark, GPNMB 
was upregulated when EZH2 was silenced in these cells.
The expression of GPNMB is also regulated by miRNAs. 
Screening of differentially expressed miRNAs in a hyper-
oxia rodent model revealed Gpnmb as a potential target of 
miR-150.31 This was further validated experimentally, as the 
upregulation of GPNMB under hyperoxia exposure in lungs 
of miR-150 knockout mice was observed.32 In human dental 
pulp stem cells, GPNMB is suppressed by miR-508-5p.33
3.2 | Transcription factors
Melanogenesis-associated transcription factor (MITF) be-
longs to the Microphthalmia family of basic helix-loop-helix 
leucine zipper transcription factors (MiTF/TFE), which regu-
late genes involved in lysosome and autophagy biogenesis.34 
In melanocytes, MITF is a master regulator of cell develop-
ment and a key transcription factor in melanoma progression; 
it controls genes that govern cell proliferation, survival, and 
differentiation.35 The involvement of MITF in GPNMB regu-
lation has been studied extensively. Overexpression of MITF 
in macrophage-like cell line RAW/C4 cells upregulated 
GPNMB expression.36 Using EMSA and luciferase transfec-
tion assays the authors confirmed that MITF binds and trans-
activates the Gpnmb promoter. This was further supported by 
the work by Loftus et al, where they identified a conserved 
element of MITF binding site on GPNMB that can drive 
GPNMB expression in melanoblasts both in a luciferase assay 
and in vivo.37 An interesting study by Gabriel et al showed 
that GPNMB is critical for macrophage infiltration in obese 
adipose tissue.38 In these cells, GPNMB was induced in the 
presence of lysosomal stress inducers in a MITF-dependent 
manner. In addition to macrophages and melanocytes, the in-
volvement of MITF in GPNMB expression was also shown 
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in human monocyte-derived dendritic cells39; treating these 
cells with a MITF inhibitor ML329 dose-dependently reduced 
GPNMB expression. A mechanistic study was conducted in 
the context of central nervous system development. The in-
tracellular domain of teneurin-1 regulated MITF-dependent 
GPNMB expression by competing for histidine triad nucleo-
tide-binding protein 1.40 In a recent study, the anti-cancer ef-
fect of inhibiting chromosomal segregation 1-like protein in 
gastric cancer cells was due to the reduction in MITF levels 
thereby suppressing GPNMB expression, further confirming 
the regulatory effect of MITF on GPNMB expression and 
function.41
Other members of the MiTF/TFE family include TFE3, 
TFEB, and TFEC. Among them, TFE3 has been shown to 
regulate GPNMB. The critical involvement of tumor sup-
pressor gene FLCN in renal cell carcinoma development was 
found to be mediated via the TFE3/GPNMB axis.42 Through 
a series of in vitro and in vivo studies, the authors showed that 
GPNMB is a downstream target of TFE3, whose expression 
was strictly dependent on FLCN inactivation. Interestingly 
MITF seems to play a minor role in the effect of FLCN, as 
MITF-induced GPNMB promoter activity was not reduced 
by FLCN in luciferase promoter assays. This shows the com-
plexity of GPNMB regulation in different cell types and dis-
ease context. A recent study by Baba et al also confirmed that 
GPNMB is a direct transcriptional target gene of chimeric 
TFE3, a fusion protein of oncogene PRCC-TFE3 responsible 
for a subtype of renal cell carcinoma.43
In addition to MITF and TFE3, the musculoaponeurotic 
fibrosarcoma (MAF) oncogene family protein K (MAFK) 
transcription factor also regulates GPNMB expression.22 In 
breast cancer cells, MAFK induced epithelial-to-mesenchy-
mal transition and promoted invasive tumor formation by 
upregulating GPNMB. Since MAFK lacks canonical tran-
scriptional activation domains,44 its effect on GPNMB tran-
scription could rely on its dimeric partner or other indirect 
mechanisms. In hepatic stellate cells, GPNMB appears to be 
regulated by the transcription factor SOX9 and plays a criti-
cal role in SOX-9 mediated liver fibrosis.45
3.3 | Cytokines and growth factors
GPNMB can be stimulated by a variety of growth factors and 
cytokines, including IFNγ (in bone marrow-derived mac-
rophages, myelogenous leukemia cell line k562, lung epi-
thelial cell line CCL-64, and CD11b+Gr1+ cells),46-48 IL1β 
(in CD11b+Gr1+ cells),47 IL10 (in human monocyte-derived 
dendritic cells),39 TGFβ (CD14+ monocytes),49 and granu-
locyte-macrophage-colony stimulating factors (GM-CSF, in 
T47D breast cancer cells).48 Other stimulants include LPS 
(microglia cells, RAW264.7 macrophages, and bone marrow-
derived macrophages)46,50,51 and α-melanocyte-stimulating 
hormone (in melanoma cells).13 UVA upregulated GPNMB 
expression in a dose-dependent manner in murine melanoma 
cells, while UVB had no effect.13 In addition to regulating 
GPNMB expression, cytokines also affect the cellular locali-
zation of GPNMB. Indeed, IFNγ and TNFα upregulated the 
surface expression of GPNMB in melanocytes but had no ef-
fect on intracellular GPNMB expression.13
The downstream signaling pathways involved in the cyto-
kine stimulation of GPNMB were elucidated in some studies. 
Metz et al showed that cytokines such as IFNγ and GM-CSF 
regulated GPNMB by p53 and other transcription factors 
induced by cytokines.48 In hepatocellular carcinoma cells, 
epithelial cell adhesion molecule (EpCAM) and CSF-1 sig-
nificantly enhanced GPNMB levels in part by c-myc.52 Bone 
morphogenic protein-2 induced GPNMB in osteoblast cul-
ture via the activation of Smad1.53 In addition, bone morpho-
genic protein-2 acted through homeodomain transcription 
factors Dlx3, Dlx5, and Msx2 during osteoblast differenti-
ation.54 Endothelin-1 upregulated GPNMB via MITF to en-
hance melanogenesis.55 The laminin-derived peptide C16 
interacted with integrin β1 which led to Src phosphorylation 
and in turn upregulated GPNMB, resulting in an invasive 
phenotype of breast cancer cells.56
4 |  GPNMB PARTNERS AND 
RECEPTORS
As mentioned earlier, GPNMB is a membrane-bound pro-
tein and it also exists in a soluble form.24,26 In either form, 
GPNMB has been shown to interact with different partners, 
including integrins, heparan sulfate proteoglycans, tyrosine 
kinase receptors, transporters, and others.
4.1 | Integrins
Since GPNMB, or osteoactivin, was identified in an osteoporo-
tic rat model,57 it has been studied extensively in regulating 
bone formation. In MC3T3-E1 osteoblast-like cells, GPNMB 
acted as a matricellular protein that stimulated osteoblast ad-
hesion by binding to integrin αvβ1 and cell surface heparan 
sulfated proteoglycans.58 This interaction is believed to lead to 
increased cell spreading, actin reorganization, and osteoblast 
differentiation. In osteoclasts, GPNMB co-immunoprecipitated 
with integrin β1 or β3; however, the functional consequence of 
this interaction is not known.59 Another reported integrin part-
ner for GPNMB is integrin α5β1.14 The RGD integrin-binding 
domain in GPNMB can promote cell invasion. Indeed, Maric 
et al showed that GPNMB binds to α5β1 fibronectin receptor 
in tumor cells through its RGD domain to enhance downstream 
signaling events essential for tumor invasion and metastasis. 
Interestingly, the RGD motif is essential for GPNMB to induce 
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α2, α5, β1, and β3 integrin subunits in breast cancer cells.14 
This possibly provides a positive feedback loop to augment the 
metastatic potential of GPNMB.
4.2 | Syndecan-4
In the immune system, GPNMB modulates adaptive im-
munity by acting through its ligand heparin sulfate proteo-
glycan syndecan-4. The extracellular domain of GPNMB 
on antigen-presenting cells suppresses T-cell activation and 
proliferation by binding to heparan sulfate-like structures on 
syndecan-4 on activated T cells.49,60-66 The critical role of 
GPNMB-syndecan-4 interaction between antigen-presenting 
cells and T cells has been suggested in different disease mod-
els, such as graft-versus-host disease, experimental autoim-
mune encephalomyelitis (EAE), and cancer.47,62-64,66 The 
antigen-presenting cells that express high levels of GPNMB 
include CD14+ monocytes and dendritic cells. In particular, 
the GPNMB-positive CD11b+Gr1+ myeloid-derived sup-
pressor cells (MDSCs) were the most expanded and most 
potent in suppressing T cells in both EAE and melanoma 
models.47,63 Blockade of GPNMB worsened autoimmune 
response and enhanced antitumor immunity in melanoma 
models. These data suggest that the GPNMB-syndecan-4 
pathway has the potential to regulate autoimmune responses 
by mediating the T cell suppressor function of MDSCs. It is 
also a potential target for immunotherapy. Indeed, toxin-con-
jugated GPNMB was shown to suppress an activated T cell-
driven response by depleting syndecan-4-positive T cells and 
deemed to be therapeutically beneficial in diseases in which 
these cells play critical pathogenic roles.60,62 A recent study 
by Kobayashi et al showed in vitro and in vivo anti-cancer 
efficacy using anti-GPNMB monoclonal antibodies to reduce 
MDSCs while increasing IFNγ-secreting T cells in the tumor 
microenvironment.65
4.3 | Tyrosine kinase receptors
In the investigation of how long non-coding RNA LINK-A is 
involved in triple negative breast cancer, Lin et al showed that 
transmembrane proteins GPNMB and EGFR interact with 
each other upon HB-EGF stimulation.20 The kinase domain 
in the EGFR intracellular domain binds to the hemITAM 
domain of GPNMB, resulting in phosphorylation of tyros-
ine 525 in GPNMB. This interaction is critical for LINK-A 
mediated recruitment of BRK and LRRK2, and subsequent 
activation of HIFα-mediated signaling in breast cancer cells.
The effect of soluble GPNMB in promoting angiogene-
sis and osteogenesis appears to be mediated through the fi-
broblast growth factor receptor-1 (FGFR-1).67 The effect of 
GPNMB in human bone marrow stromal cells and endothelial 
cells was blocked by knocking down FGFR-1 or FGFR-1 in-
hibitor SU5402.
4.4 | Na+/K+-ATPase
In amyotrophic lateral sclerosis (ALS) patients, elevated 
GPNMB levels were observed in the cerebrospinal fluid 
and serum.68 Tanaka et al showed that the ectodomain of 
GPNMB was protective against mutant superoxide dismutase 
1- induced neurotoxicity via the activation of the PI3K/Akt 
and MEK/ERK pathways.68 In a follow-up study the group 
utilized Membrane Protein Library/BLOTCHIP-MS tech-
nology to perform a comprehensive analysis of cell surface 
proteins/receptors, and eventually identified the alpha subu-
nits of Na+/K+-ATPase as binding partners of the soluble 
GPNMB.69 This was further confirmed by co-immunopre-
cipitation as well as functional assays incorporating Na+/
K+-ATPase inhibitor ouabain and knocking down the alpha 
subunits of Na+/K+-ATPase. Both inhibitor and siRNA of 
Na+/K+-ATPase effectively blocked the protective effect of 
GPNMB against stress-induced cell death and PI3K/Akt and 
MEK/ERK activation. Although Na+/K+-ATPase is a trans-
porter, it has been reported to be able to function as a non-
canonical receptor to activate the PI3K/Akt and MEK/ERK 
pathways.70
4.5 | CD44
The soluble form of GPNMB has been shown to mediate its 
effect on mesenchymal stem cells, osteoclasts, astrocytes, 
and adipocytes through acting on CD44. Also referred to as 
P-glycoprotein 1, CD44 is a transmembrane glycoprotein that 
is widely expressed on various cell types. It is involved in cell-
matrix or cell-cell interactions to modulate various cellular 
events including cell proliferation, adhesion, migration, as well 
as lymphocyte activation and extravasation.71 CD44 has multi-
ple variants and it also undergoes post-translational modifica-
tions such as N- and O-glycosylation. These unique qualities 
and their abundance on cell surfaces are likely the reason for its 
diverse cellular activity. The first study that identified CD44 as a 
GPNMB receptor was conducted by Yu et al. They showed that 
M2 macrophages secreted higher levels of GPNMB than M1 
macrophages, and this subsequently promoted the proliferative 
and migratory properties of mesenchymal stem cells.72 They fur-
ther demonstrated that CD44 was the receptor for macrophage-
released GPNMB on these stem cells. Via interacting with 
CD44, GPNMB stimulated ERK and Akt signaling pathways 
in these cells. This study provided the framework for how mac-
rophages, through GPNMB, regulates mesenchymal stem cells.
To dissect the function and signaling mechanisms of 
GPNMB in osteoclasts, Sondag et al showed that GPNMB 
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dose dependently inhibited receptor activator of nuclear fac-
tor-k B ligand (RANKL)-induced osteoblast differentiation 
in both bone marrow-derived osteoclast progenitor cells and 
in mice.73 In addition, the inhibitory effect of GPNMB on 
RANKL-induced ERK phosphorylation was mediated by 
CD44. These data suggest that GPNMB negatively regulates 
osteoclastogenesis and that CD44/ERK activation is critical 
for this process. The CD44/GPNMB axis is also critical in 
neurodegenerative diseases including Parkinson's disease. 
Elevated levels of GPNMB and CD44 were observed in the 
substantia nigra of human Parkinson's disease brains and 
in the astrocytes of an animal model for Parkinson's dis-
ease.74 GPNMB treatment showed neuroprotective effect in 
an astrocyte cell line and primary mouse astrocytes. Using 
primary mouse astrocytes isolated from CD44 knockout 
mice, it was confirmed that the anti-inflammatory effects of 
GPNMB were CD44-mediated. Interestingly, GPNMB was 
recently shown to promote fatty acid synthesis in adipocytes 
through CD44-Akt-SREBP1c in adipocytes.75
4.6 | Others
Chung et al showed that GPNMB is a pathogen recognition 
receptor for dermatophytic fungi.76 GPNMB on dendritic 
cells can directly bind to the cell wall of Trichophyton ru-
brum and Microsporum audouinii to transduce signals via its 
membrane-proximal YxxI sequence thereby resulting in the 
activation of the dendritic cells.
In hepatic macrophages and stellate cells, GPNMB was 
found to interact with calnexin.77 Located in the endoplasmic 
reticulum, calnexin is a chaperone protein that assists folding 
and assembly of N-linked glycoproteins. Although the mech-
anism of the direct interaction between GPNMB and calnexin 
is not known, the authors posited that GPNMB, overexpressed 
in hepatic stellate cells, binds to calnexin thereby exerts an-
ti-oxidative properties and subsequently inhibits liver fibrosis.
5 |  PHYSIOLOGICAL FUNCTIONS
GPNMB is expressed in a variety of tissues with the high-
est expression in the adipose tissue and skin.78,79 It is also 
expressed in multiple cell types, including osteoclasts, osteo-
blasts, immune cells, melanocytes, to name a few. The wide 
expression of GPNMB points to the involvement of this pro-
tein in many physiological processes.
5.1 | The bones
GPNMB is involved in bone development. It controls 
the differentiation and activities of both osteoclasts and 
osteoblasts.59,80-82 In osteoblasts, blockade of GPNMB in-
hibited differentiation, while the overexpression of GPNMB 
enhanced osteoblast differentiation and function.80 The 
osteogenic activity of GPNMB was also confirmed in ani-
mal models.81,83 Also expressed in osteoclasts, the role of 
GPNMB in osteoclasts is less clear. Mutation of Gpnmb led 
to increased osteoclastogenesis but impaired bone resorp-
tion.82 Recombinant GPNMB inhibited RANKL-mediated 
osteoclast differentiation via the activation of the CD44/
ERK pathway.73 In contrast, other studies have suggested 
that GPNMB stimulates osteoclast differentiation and func-
tion.59,84 More studies are needed to investigate the involve-
ment of GPNMB in osteoclast function.
5.2 | The skin
GPNMB is highly expressed in the skin. It is found to be 
predominantly expressed in melanocytes, which are lo-
cated in the basal layer.10,79 It is also expressed in other cell 
types of the skin, including keratinocytes and Langerhans 
cells.13,49 Melanosomes are intracellular vesicles that pro-
duce, package, and store melanin in melanocytes. GPNMB 
is localized in early, stage III, and stage IV melanosomes, 
with relatively higher amounts detected in mature mela-
nosomes.10 GPNMB is critical for the biogenesis of early 
melanosomes, as knockdown of GPNMB led to a signifi-
cant decrease in the number of melanosomes in melano-
cytes.85 GPNMB also mediates melanocyte adhesion to 
keratinocytes in a RGD-dependent manner.13 The signifi-
cance of GPNMB in the skin is highlighted by the study 
by Yang et al, where they showed that GPNMB truncat-
ing alleles are the cause of autosomal-recessive amyloido-
sis cutis dyschromica, a rare variant of primary cutaneous 
amyloidosis that causes localized hyperpigmentation and 
hypopigmentation.86
GPNMB is also involved in wound repair. Yu et al ele-
gantly showed that GPNMB, secreted from macrophages, 
signals mesenchymal stem cells to be recruited to the site of 
skin injury.87 These mesenchymal stem cells can, in turn, pro-
mote the M2 polarization of macrophages for rapid wound 
repair. The authors further showed that macrophages in di-
abetic wounds showed diminished levels of GPNMB, and 
topical treatment of GPNMB not only restored mesenchymal 
stem cell recruitment, but also increased M2 macrophages 
and enhanced wound closure.
5.3 | The central nervous system
GPNMB is widely expressed in the normal central nervous 
system (CNS) of adult rats, and mainly colocalized with 
microglia/macrophages.88 Various studies have suggested 
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that GPNMB is neuroprotective. Transgenic mice with 
GPNMB overexpressed demonstrate significantly ame-
liorated infarct volume after ischemia-reperfusion injury 
compared to wild-type mice.89 This effect appears to be 
mediated by the ectodomain of GPNMB, which increases 
phosphorylated-Akt and ERK. In addition, GPNMB shows 
neuroprotective effects in NSC-34 motor neurons via 
the Na+/K+-ATPase/PI3K/Akt and MAPK/ERK axis.69 
GPNMB also improves both spatial and non-spatial mem-
ory.90 In both GPNMB transgenic mice and mice treated 
with the soluble form of GPNMB, the memory improve-
ment was associated with increased levels of the α-amino-
3-hydroxy-5-methylisoxazole-4-propionate receptor 
subunit GluA1.
GPNMB is also involved in neuroinflammation. Treating 
an astrocyte cell line or mouse astrocytes with GPNMB at-
tenuated inflammatory responses in these cells, and this pro-
cess appears to be CD44-dependent.74 Interestingly elevated 
levels of GPNMB are observed in the CNS in patients with 
ALS, Parkinson's disease, and Alzheimer's disease.68,74,91,92 
Under these conditions, GPNMB might be neuroprotective 
and promoting neuron survival. Studies exploring GPNMB 
as a possible therapeutic target or biomarker for these dis-
eases are currently underway.93
5.4 | The immune system
GPNMB has been implicated in both adaptive and innate 
immunity.64,76 In immune cells, GPNMB expression is de-
tected in monocytes, lymphocytes, dendritic cells, and gran-
ulocytes.78 In innate immunity, GPNMB is shown to be a 
pathogen recognition receptor for dermatophytic fungi.76 
Moreover, the anti-inflammatory role of GPNMB was 
shown in macrophages.46 It was reported that the expres-
sion of GPNMB is inhibited in RAW264.7 cells exposed to 
LPS. In addition, GPNMB reduced the LPS/IFNγ-induced 
secretion of IL-6 and IL-12p40. The results indicated that 
GPNMB suppressed pro-inflammatory cytokine production 
in macrophages, as was also shown in a model of experimen-
tal colitis.51 The notion that GPNMB-positive macrophages 
negatively regulate inflammation is further supported by 
the observation that anti-inflammatory M2 macrophages 
expressed more GPNMB than the pro-inflammatory M1 
macrophages.72 Moreover, M2 polarization from bone mar-
row-derived macrophages was inhibited when GPNMB was 
knocked down in these cells, while M1 polarization was 
enhanced.94 The GPNMB-mediated anti-inflammatory ef-
fect on macrophages has been demonstrated in wound heal-
ing,87 fibrosis,94,95 kidney injury,96 as well as inflammatory 
responses in the adipose tissue.38,77 The involvement of 
GPNMB in the innate immune response was also implicated 
in autoimmune pigmentary glaucoma in mice.97
Various studies support the role of GPNMB in controlling 
adaptive immunity. As we have discussed previously, the 
high expression of GPNMB on antigen-presenting cells re-
presses T-cell activation via binding to syndecan-4.49,61 The 
ability of GPNMB to modulate adaptive immunity has been 
documented in various disease contexts including graft-ver-
sus-host disease, EAE, and cancer.47,62-64,66
5.5 | Metabolism and immunometabolism
GPNMB is linked to obesity-driven inflammation in adipose 
tissue. This is not surprising, as the adipose tissue has a high 
amount of GPNMB.78 Microarray analysis in mice fed with 
high-fat diet revealed Gpnmb as one of the top upregulated 
genes.98 Similar results were obtained from the transcriptomic 
analysis of backfat tissue extracted from fat and lean pigs; 
GPNMB is expressed higher in fat pigs.99 The association of 
GPNMB with adipose tissue and inflammation is also indi-
cated in Gaucher disease, which is a lysosomal storage disor-
der characterized by macrophage lipid storage problems and 
deficiency in lysosomal acid β-glucosidase. Elevated GPNMB 
levels were found in a mouse model and patients of Gaucher 
disease.100,101 GPNMB levels not only correlated with overall 
disease severity but also decreased when patients were treated.
The exact function of GPNMB in adipose tissue is not 
known. In a recent study, Gong et al showed that hepatic 
GPNMB stimulates lipogenesis in adipocytes via binding to 
CD44, thereby triggering the PI3K-Akt-mTOR-SREBP1c 
signaling pathway.75 Excessive GPNMB increases fat stor-
age in adipose tissue and exacerbates insulin resistance. In 
addition, treatment with neutralizing antibodies targeting 
GPNMB attenuated lipogenesis and adipocyte size, as well 
as improved metabolic parameters in mice. GPNMB also af-
fects adipose tissue macrophages. It is highly expressed in 
macrophages in adipose tissue of obese mice and humans.38 
GPNMB is induced by lysosomal stress inducers via MITF 
in macrophages, and potentiates alternative macrophage ac-
tivation, as indicated by IL-4 mediated arginase-1 induction. 
These results suggest that GPNMB plays a critical role in the 
phenotype and function of obesity-induced adipose tissue 
macrophages. The involvement of macrophage GPNMB in 
obesity was also shown by Katayama et al, where overex-
pression of GPNMB in transgenic mice ameliorated fat ac-
cumulation and fibrosis in the liver in a diet-induced obesity 
model.77 GPNMB in hepatic macrophages interacted with 
calnexin to reduce oxidative stress.
5.6 | The eyes
GPNMB was found in high amounts in the outer layer of the 
retina during early development, while the expression was 
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restricted in the retinal pigment epithelium and iris later in 
development.102 It was suggested that based on the sequence 
homology to melanosomal proteins and endosomal localiza-
tion, GPNMB might be involved in the development of the 
retinal pigment epithelium and iris. In addition to the mul-
tiple pigmented cells of the eye such as melanocytes of the 
iris and pigmented cells of the iris epithelium, GPNMB was 
found to localize to ocular antigen-presenting cells, specifi-
cally macrophages and dendritic cells.97 A spontaneous mu-
tation within the Gpnmb locus that creates a truncated form of 
GPNMB has been identified in DBA/2J mice. Homozygous 
mice exhibit autoimmune pigmentary glaucoma and compro-
mising ocular immunosuppression.103 It was later shown that 
GPNMB influenced the glaucoma phenotype of these mice 
through mechanisms independent of adaptive immunity.97
5.7 | Others
GPNMB is involved in odontogenesis.104 This is not surpris-
ing, since odontoblast-like differentiation of dental pulp cells 
is similar to human bone marrow stromal cells osteogen-
esis. Knockdown of GPNMB in dental pulp cells inhibited 
odontoblastic differentiation, suggesting that GPNMB pro-
moted odontoblast differentiation in these cells. Later it was 
shown that miR-508-5p regulated the osteogenesis of human 
dental pulp stem cells by targeting GPNMB.33
The soluble form of GPNMB shows potent angiogenic 
properties.25,67,105 In a mouse model of mammary carci-
noma, GPNMB-mediated enhancement of tumor growth 
was accompanied by increased vascular density.25 In ad-
dition, the ectodomain of GPNMB, shed by ADAM10, 
promoted endothelial cell migration. In human umbilical 
vascular endothelial cells, soluble GPNMB induced angio-
genesis by activating FGFR-1 and the corresponding down-
stream molecule ERK1/2.67 Similar results were shown by 
Narasaraju et al where the protective effect against hyperoxia 
induced-impaired vascular growth impairment and increase 
in cellular infiltrates in miR-150 knockout mice was medi-
ated through the elevated levels of GPNMB.105 The pro-an-
giogenic property of GPNMB provides a mechanistic tool 
for cancer cells to promote tumorigenesis. Indeed, GPNMB 
silencing in glioma cells inhibited cell growth. In addition, 
conditioned media from these transfected cells significantly 
reduced tube formation in endothelial cells.106
6 |  IMPLICATIONS IN 
AUTOIMMUNITY
GPNMB has been associated with kidney disease107,108 and 
promotes repair in kidney injury.96 Therefore, it is not sur-
prising that there are reports associating GPNMB with lupus 
nephritis. Indeed, elevated GPNMB levels were found in the 
urine and exosomes in a lupus patient with acute lupus ne-
phritis.108 In addition, immunostaining of GPNMB showed 
cortical tubular expression in kidney biopsies from a patient 
with lupus nephritis. A recent study profiling the immune cell 
landscape in kidney samples from lupus nephritis patients 
using single-cell RNA sequencing revealed the upregula-
tion of GPNMB in myeloid cells.109 In particular, GPNMB 
appears to be primarily expressed in phagocytic CD16+ 
macrophages, M2-like CD16+ macrophages, and to a lesser 
extent in tissue-resident macrophages (Figure 2). This echoes 
what was found in animal models of lupus. Characterization 
of renal mononuclear phagocyte populations in the lupus 
mouse model NZB/W showed that phagocytic F4/80hi/
CD11cint macrophages were located throughout the kidney 
interstitium. They were associated with tissue damage and 
disappeared after remission.110 Using Affymetrix Gene-
Chip arrays, confirmed by qPCR, Gpnmb was upregulated 
in F4/80hi cells from nephritic kidneys compared with young 
kidneys and downregulated after disease remission. The un-
derlying mechanisms of how GPNMB is involved in lupus 
nephritis warrant further examination.
In psoriatic arthritis, GPNMB was upregulated in synovial 
membranes compared to tissues obtained from healthy sub-
jects.111 GPNMB was among the most highly differentially 
expressed genes found in the gene array analysis (147 fold 
change vs control). It was also elevated in peripheral blood 
cells from psoriatic arthritis patients. The serum levels of 
GPNMB were elevated in patients with psoriatic arthritis 
compared to healthy controls, while no difference was ob-
served in patients with rheumatoid arthritis or ankylosing 
spondylitis, suggesting that GPNMB could be used as a bio-
marker for psoriatic arthritis. Analysis of recent single-cell 
RNA sequencing data derived from the synovial tissue of 
patients with rheumatoid arthritis and osteoarthritis revealed 
GPNMB expression in the majority of synovial fibroblasts 
and tissue-infiltrating monocytes (Figure 3). In monocytes, 
cells within a NUPR1+ subset which correlated inversely 
with tissue inflammation demonstrated the highest levels and 
frequency of GPNMB expression.112
GPNMB has been shown to be possibly implicated in the 
pathogenic mechanisms underlying Takayasu arteritis in the 
context of functional genomics.113
Our group revealed a functional effect of a non-coding 
Takayasu arteritis-associated genetic variant (rs2069837) 
located within an enhancer region in IL6 on regulating the 
expression of GPNMB, a gene located more than 500  kb 
away from this risk locus. By incorporating bioinformatics 
analysis with experimental assays, we showed that through 
CTCF-mediated chromatin looping, the Takayasu arteritis 
risk allele in this genetic variant results in the increased re-
cruitment of MEF2 and accumulation of histone deacetylases 
that repress GPNMB expression. These results were further 
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supported by significantly lower GPNMB mRNA expression 
levels in monocyte-derived macrophages from individuals 
with the homozygous risk genotype compared to the het-
erozygous genotype. This work characterized the functional 
consequences of the disease-associated risk locus in IL6 and 
suggested that GPNMB might be involved in the pathogene-
sis of Takayasu arteritis.There are no reports suggesting the 
involvement GPNMB in the pathogenesis of systemic sclero-
sis, despite data indicating that GPNMB attenuates fibrosis 
in various disease models. Hepatic fibrosis was reduced in 
Gpnmb-transgenic rats, accompanied by the downregulation 
of TIMP1, 2, alpha-smooth muscle actin, collagen, and plate-
let-derived growth factor receptors.114 The protective effect 
of GPNMB in liver fibrosis has been attributed to its role 
in macrophages. The CD11Bhi F4/80int Ly-6Clo macrophage 
subset was found to be most abundant in livers during fibro-
sis resolution and expressed MMPs, in contrast to profibrotic 
Ly-6Chi macrophages.115
The gene expression profiles of these Ly-6Clo macro-
phages favor scar resolution, including the upregulation of 
Gpnmb. The role of the macrophage-mediated protective ef-
fect of GPNMB was also suggested in the diet-induced obe-
sity model afflicted with liver fibrosis.77 Further, GPNMB 
F I G U R E  2  GPNMB expression in kidney biopsy tissues in lupus nephritis. A, TSNE plot generated from unsupervised clustering analysis of 
single-cell RNA-seq data from kidney biopsies of lupus patients generated by the Accelerating Medicines Partnership (AMP) project (right panel). 
Feature plot showing GPNMB expression, revealing three myeloid cell clusters with GPNMB expression (CM1, CM4, and CM2) (left panel). B, 
Bar plot showing the percentage of GPNMB expressing cells in kidney-infiltrating cell clusters and dot pot showing relative GPNMB expression 
levels. This figure was generated using the viewing browser https://immun ogeno mics.io/ampsl e/. CM0, Inflammatory CD16+ macrophages; CM1: 
Phagocytic CD16+ macrophages; CM2, Tissue-resident macrophages; CM3, Conventional dendritic cells; CM4, M2-like CD16+ macrophages; 
CT0a, Effector memory CD4+ T cells; CT0b, Central memory CD4+ T cells; CT1, CD56dim CD16+ NK cells; CT2, Cytotoxic T lymphocytes; 
CT3a, Tregs; CT3b, TFH-like cells; CT4, GZMK+ CD8+ T cells; CT5a, Resident memory CD8+ T cells; CT5b, CD56bright CD16- NK cells; CT6, 
ISG-high CD4+ T cells; CB0: Activated B cells; CB1, Plasma cells/Plasmablasts; CB2a, Naive B cells; CB2b, Plasmacytoid dendritic cells; CB3, 
ISG-high B cells; CD0, Dividing cells; CE0, Epithelial cells
F I G U R E  3  GPNMB expression in synovial tissue. Feature 
plot showing GPNMB expression using single-cell RNA-seq data in 
synovial tissue from rheumatoid arthritis and osteoarthritis patients 
generated by the Accelerating Medicines Partnership (AMP) project. 
This figure was generated using the viewing browser https://immun 
ogeno mics.io/ampra /
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secreted from macrophages was critical for mesenchymal 
stem cell recruitment in wounds to promote tissue repair.87 
In addition to macrophages, GPNMB also exerts its effect 
on fibroblasts. Stimulating fibroblasts with a soluble form of 
GPNMB activated ERK1/2 and p38 pathways and induced 
MMP-3 expression.26 Since GPNMB promotes angiogene-
sis,25,67,105 it could also alleviate the prominent vascular com-
plications seen in patients with systemic sclerosis.
As discussed earlier, GPNMB is critical in the interac-
tion between dendritic cells and T cells. GPNMB on anti-
gen-presenting cells inhibits T-cell activation by binding to 
syndecan-4 on T cells.49,61 In the EAE model for multiple 
sclerosis, the GPNMB-syndecan-4 pathway regulates au-
toimmune responses by mediating the T-cell suppressor 
function of CD11b+Gr1+ MDSCs.63 The role of GPNMB in 
regulating T cell activation in autoimmune diseases should be 
further investigated in the future.
7 |  CONCLUSION AND FUTURE 
PERSPECTIVES
GPNMB is widely expressed in many tissues and is involved 
in regulatory roles in various cellular functions. Because of 
its functions in cell adhesion, migration, proliferation, and 
differentiation in various cell types, GPNMB has been im-
plicated in a variety of pathological conditions. Aberrant 
GPNMB expression has been reported in patients with neuro-
degenerative diseases,68,74,91,92 fatty liver disease,77 Gaucher 
disease,101 and several types of cancer,3,116 to name a few. 
Although the involvement of GPNMB in autoimmune dis-
eases has not been fully elucidated, given the involvement of 
GPNMB in immune responses, osteogenesis, angiogenesis, 
and fibrosis, it is possible that GPNMB plays an important 
role in the pathogenesis of autoimmune diseases. Indeed, 
we discussed current findings related to the involvement of 
GPNMB in several immune-mediated diseases as summa-
rized in Figure 4.
GPNMB could also serve as a potential biomarker for 
a number of diseases. Elevated serum levels of GPNMB 
have been reported in several diseases and its expression 
correlated with disease severity or prognosis in a few con-
ditions.77,101,108,117 Higher serum levels of GPNMB were 
detected in patients with psoriatic arthritis, but not in pa-
tients with rheumatoid arthritis or ankylosing spondylitis.111 
Moreover, urine GPNMB might be a potential biomarker for 
lupus nephritis.108 A recent report suggested that the DNA 
methylation status of GPNMB can be used as a biomarker 
to assess the progression of colorectal lesions.27 As DNA 
methylation has been shown to be involved in autoimmune 
diseases such as systemic sclerosis and lupus,118,119 it will be 
interesting to examine the expression and DNA methylation 
status of GPNMB in these diseases.
Initially found to play multiple roles in the bone, our un-
derstanding of the function of GPNMB has since evolved 
tremendously. Indeed, the anti-inflammatory properties of 
GPNMB and evidence for the dysregulation of GPNMB ex-
pression in multiple immune-mediated diseases, suggest that 
GPNMB regulation or GPNMB-dependent pathways might 
serve as a novel therapeutic target in autoimmunity. However, 
more research is needed to fully characterize the role of 
GPNMBupon the pathogenesis and progression of autoim-
mune diseases.
ACKNOWLEDGMENTS
This work was supported by the National Institute of Arthritis 
and Musculoskeletal and Skin Diseases of the National 
Institutes of Health grant number R01 AR070148.
F I G U R E  4  Schematic representation demonstrating potential involvement for GPNMB in multiple autoimmune diseases. Dysregulation of 
GPNMB, particularly the soluble form, could play a role in systemic sclerosis, as GPNMB mediates pro-angiogenic effects on endothelial cells, 
anti-fibrotic potential on fibroblasts, and anti-inflammatory properties in macrophages. GPNMB-expressing macrophages also play a role in lupus 
nephritis and Takayasu arteritis. The expression of GPNMB in the synovial tissue has been reported in both psoriatic arthritis and rheumatoid 
arthritis patients. Since GPNMB on antigen presenting cells, such as dendritic cells, inhibits T-cell activation by binding to syndecan-4 on T cells, 
this interaction might be relevant to T cells-driven autoimmune diseases
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